Supernus Pharmaceuticals Launches ADHD Series with Jay Glazer
Supernus Pharmaceuticals is teaming up with Jay Glazer to introduce an ADHD-focused content series on the All About ADHD YouTube channel, featuring insights from his wife, Rosie Glazer.
New Content Series Launch
This series, debuting in May for Mental Health Awareness Month, explores how ADHD impacts relationships. Jay shares his experiences managing ADHD using Qelbree, a non-stimulant treatment. The initiative aims to foster open discussions about ADHD’s challenges, highlighting its effects on both individuals and their support systems.
Potential Benefits
- The partnership with Jay Glazer signifies a strong commitment to ADHD awareness, which could enhance Supernus Pharmaceuticals’ brand reputation.
- This personal narrative has the potential to resonate with families affected by ADHD, possibly increasing engagement with Qelbree.
- Launching during Mental Health Awareness Month aligns the series with a significant event, likely boosting visibility for Qelbree.
Potential Drawbacks
- Concerns about Qelbree’s side effects, including increased suicidal thoughts, might worry patients and healthcare providers.
- The focus on a public figure’s journey may lead to perceptions that marketing takes precedence over patient safety.
- References to side effects could deter potential users, impacting public perception of Qelbree.
Frequently Asked Questions
What is the focus of Jay Glazer’s new content series?
The series addresses ADHD’s impact on relationships, featuring experiences from Jay and Rosie Glazer.
Where can I watch the new ADHD series?
The series is available on the All About ADHD YouTube channel starting in May.
What is Qelbree and who is it for?
Qelbree is a non-stimulant medication for treating ADHD in individuals aged 6 and older.
How does ADHD affect relationships according to the series?
The series illustrates that ADHD affects not only the individual but also their support networks.
What should patients consider before starting Qelbree?
Patients should consult a doctor regarding medications and any history of suicidal thoughts before beginning Qelbree.
Disclaimer: This summary is based on a press release from GlobeNewswire. See the full release here.
$SUPN Congressional Stock Activity
Members of Congress have traded $SUPN stock once in the past six months, with one purchase and no sales.
Here’s a breakdown of recent congressional trades involving $SUPN:
$SUPN Insider Trading Activity
In the past six months, insiders have executed six trades on $SUPN stock, all sales and no purchases.
- PADMANABH P. BHATT (Sr. VP of IP, CSO) sold 34,245 shares for approximately $1,294,349.
- JONATHAN RUBIN (SVP, Chief Medical Officer) sold 927 shares for around $36,292.
$SUPN Hedge Fund Activity
During the last quarter, 142 institutional investors increased their positions on $SUPN, while 144 reduced theirs.
Recent significant transactions include:
- PACER ADVISORS, INC. sold 1,193,828 shares (-74.7%) for about $39,097,867.
- SOFINNOVA INVESTMENTS, INC. acquired 520,678 shares for approximately $17,052,204.
- KRENSAVAGE ASSET MANAGEMENT, LLC added 431,986 shares for an estimated $14,147,541.
- WOODLINE PARTNERS LP sold 423,828 shares (-100.0%) for approximately $13,880,367.
- ARMISTICE CAPITAL, LLC acquired 360,000 shares (+7.4%) for about $11,790,000.
- POLAR CAPITAL HOLDINGS PLC sold 325,590 shares (-19.3%) for an estimated $10,663,072.
- BLACKROCK, INC. sold 313,384 shares (-3.1%) for around $10,263,326.
Full Release
ROCKVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals expands its partnership with TV personality Jay Glazer to launch a content series featuring Rosie Glazer, debuting in May for Mental Health Awareness Month. This four-part series will provide unique insights into how ADHD impacts relationships and illustrates Jay’s treatment journey with Qelbree, a non-stimulant ADHD medication for ages 6 and older.
# Jay and Rosie Glazer Discuss ADHD Management and Qelbree Treatment
Overview of the Discussion
Jay Glazer highlighted his support system during his ADHD journey, primarily referencing Rosie. He stated, “This series creates space for honest conversations about how ADHD affects not just the individual, but also their loved ones.” Glazer noted that recognizing and discussing his ADHD symptoms has improved their teamwork in managing the condition, particularly through the medication Qelbree, which has positively impacted him.
Jack Khattar, President and CEO of Supernus Pharmaceuticals, emphasized that ADHD affects both individuals and their support systems. He described the content series as an extension of their partnership, indicating that Jay and Rosie’s experiences resonate with many affected by ADHD. Khattar reaffirmed Supernus’s commitment to developing treatment solutions for ADHD and fostering a more informed community.
To learn more about Qelbree, patients should consult a doctor to discuss medication options.
Series Availability
The first episode of the series, Jay & Rosie Glazer’s ADHD Story: Real Life, Real Change, is now available for viewing here.
Qelbree Information
Qelbree® (viloxazine extended-release capsules) is prescribed to treat ADHD in adults and children aged 6 years and older.
Safety Information
Qelbree may increase suicidal thoughts and actions within the first few months of treatment. Patients should monitor any mood changes and consult a doctor if necessary. The medication should not be taken with monoamine oxidase inhibitors (MAOIs) or if there is a history of specific drug interactions.
Qelbree can increase blood pressure and heart rate, requiring monitoring by a healthcare provider. Patients with bipolar disorder should be wary of potential manic episodes. Users should not drive or operate heavy machinery until they understand how Qelbree affects them.
The common side effects for patients aged 6 to 17 include sleepiness, irritability, and nausea. Adults may experience insomnia and dry mouth, among others. It’s crucial to report any adverse effects to the FDA.
For full prescribing information, including warnings and medication guides, visit here.
Qelbree is available in 100 mg, 150 mg, and 200 mg capsules.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for central nervous system (CNS) diseases, including ADHD and other neurological disorders.
For more details, please visit www.supernus.com.
Contact Information
Jack A. Khattar, President and CEO
Timothy C. Dec, SVP and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
Investor Contact:
Peter Vozzo
ICR Healthcare
(443) 213-0505
[email protected]
Media Contact:
Katherine Dunleavy
Burson
(212) 601-3019
[email protected]
This article was originally published on Quiver News.
The views expressed herein do not necessarily reflect those of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
